Cited by 27Alzheimer's disease research and treatmentsAmyotrophic Lateral Sclerosis ResearchNeuroinflammation and Neurodegeneration Mechanisms

Identification of key amino acids responsible for the distinct aggregation properties of microtubule-associated protein 2 and tau

Open access
Xie, Ce, Soeda, Yoshiyuki, Shinzaki, Yuki, In, Yasuko, Tomoo, Koji, Ihara, Yasuo, Miyasaka, Tomohiro·2015·Journal of Neurochemistry

Abstract

The carboxyl‐terminal sequence of tau composes the framework for its intracellular inclusions that appear in diverse neurodegenerative disorders known as tauopathies. However, microtubule‐associated protein 2 (MAP 2), which contains a homologous carboxyl‐terminal sequence of tau, is undetectable in the mature tau inclusions. The mechanisms underlying this phenomenon have remained largely unknown. Here, we show that tau and MAP 2 have different aggregation properties: tau aggregates to form filaments but MAP 2 remains to be granules. Exchanging 221YKPV224 of tau (0N3R) near the PHF 6 motif for 340TKKI343 of MAP 2c profoundly changed aggregation properties, suggesting that the YKPV motif is important for filament formation, whereas the TKKI motif is for granule formation. Thus, these minimal sequences may determine the different fates of tau and MAP 2 in the formation of inclusions in tauopathies. image Tau and microtubule‐associated protein 2 (MAP2) are homologous microtubule‐associated proteins in neurons. So far, it is largely unknown why tau but not MAP2 is selectively involved in the filamentous inclusions (neurofibrillary tangles, NFT) formation in tauopathies, including Alzheimer's disease. In this study, we found that the difference of only two amino acids in tau and MAP2 sequences may determine their different fates in tauopathies. These results may lead to the elucidation of tau deregulation in pathological conditions.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/jnc.13228

Cites

17 of 17 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • In vitro experiments have demonstrated that MAP2 forms either fibrillar or granular, non-amyloidogenic aggregates.

    “In vitro experiments have demonstrated that MAP2 forms either fibrillar (30, 31) or granular, non-amyloidogenic aggregates (32, 33).”

    From MAP2 caps tau fibrils and inhibits aggregation (2023) · cites this paper as [33]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Xie, C., Soeda, Y., Shinzaki, Y., In, Y., Tomoo, K., Ihara, Y., & Miyasaka, T.
Affiliations
  • Doshisha University (JP)
  • Center for Development of Advanced Medicine for Dementia, National Center for Geriatrics and Gerontology (JP)
  • Osaka University of Pharmaceutical Sciences (JP)
Corresponding author
Miyasaka, Tomohiro
Venue
Journal of Neurochemistry
Publisher
Wiley
Published
2015-08-26
Volume
135
Issue
1
Pages
19-26
ISSN
  • 0022-3042 (ISSN-L)
  • 1471-4159
OpenAlex
W1878810938
Cited by
27
References
17
Citations by year
2024: 2 · 2023: 5 · 2022: 3 · 2021: 3 · 2020: 1 · 2019: 3 · 2018: 5 · 2017: 3 · 2016: 2
FWCI
2.46
Type
journal article
Language
en
Open access
Locations
  • Journal of Neurochemistry (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
Funders
  • Grant-in-Aid for Scientific Research KAKENHI
  • Grant-in-Aid for Young Scientists (B) (20700324, 24700368)
  • Grant-in-Aid for Challenging Exploratory Research (22650074)
  • Core Research for Evolutional Science and Technology CREST
  • Japan Science and Technology Agency (JST)
  • Japan Society for the Promotion of Science (JSPS)
  • Grant-in-Aid for Scientific Research on Innovative Areas (26117004)
Topics
  • Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
  • Health Sciences › Medicine › Neurology › Amyotrophic Lateral Sclerosis Research
  • Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
Keywords
tau protein, MAP2, tauopathy, protein aggregation, neurofibrillary tangles, carboxyl-terminal sequence, filamentation, granule formation, Alzheimer's disease, neurodegeneration
MeSH terms
Alzheimer Disease, Amino Acids, Humans, Microtubule-Associated Proteins, Neurons, Neurofibrillary Tangles, tau Proteins, Tauopathies

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review